Clinical News

A look at DUR alerts-why they started, where they are now, and where they need to go.

Authorities putting more pressure on supplement manufacturers.

Cangrealor is the first FDA-approved P2Y12 inhibitor.

How Walgreens is helping pharmacists be more involved than ever in helping cancer patients.

A look at PDMPs in PA-what they are doing and how they are helping patients.

Noctiva is the first agent approved to temporarily decrease urine production in adults with nocturia from various causes.

Former FDA deputy commissioner is nominated to take the top job, but financial ties may bind for him.

Analysts and columnists from the left and right have had time to react to the new healthcare replacement plan. What are they saying?

Jonathan C. Roberts is named Executive Vice President and COO.

Meijer will improve and expand pharmacies across its new and remodeled stores.

A meta-analysis casts light on therapy compliance issues among patients with different mental health disorders.

An ageing population and an increase in government spending mean that NHE will only be growing in the coming decade.

In his address to Congress, Trump hinted at what could be in the future for healthcare reform.

Rite Aid and Albertsons expand naloxone Access, hoping to curb the opioid epidemic.

Rare Disease Day is held every year on the last day of February to help spread awareness about rare diseases and the people they impact.

A look at four important drug studies and stories that you need to know about.

A new CDC study shows that drug overdose deaths have been on the rise and are likely to keep rising.

Review of new drug Ivabradine (Corlanor) approved by the FDA for the management of heart failure.

New drug review

Use inhaled corticosteroids sparingly and only in these circumstances in patients with COPD. Details here.

As community pharmacies strive to play a greater role in population health management, could TB testing be an important item on the service menu?

FDA approved ixazomib (Ninlaro, Takeda) in combination with lenalidomide and dexamethasone

While many aspects of diabetes care are universal, patients with type I diabetes (T1D) often face a unique set of obstacles and challenges.

FDA approved EpclusaTM (sofosbuvir and velpatasvir, (SOF-VEL) for adults with chronic hepatitis C infection both with compensated cirrhosis or without cirrhosis as well as in combination with ribavirin for hepatitis C with decompensated cirrhosis.

Despite evidence that optimal glycemic control can help reduce disease progression and complications, most patients do not achieve recommended treatment goals.

A randomized controlled study has found that oral syringes are more accurate than dosing cups when parents measure doses of liquid medications for their children.

Pharmacists’ involvement in cardiovascular risk screening resulted in referrals to physicians for patients who were under-diagnosed.

Researchers found that estimated coverage for RV at 19 to 35 months of age lags behind the other vaccines recommended at ages two, four, and six.

Two new biosimilar announcements are expected to increase the uptake of the biosimilar infliximab to Johnson & Johnson’s Remicade for rheumatoid arthritis, Crohn’s disease, and other inflammatory conditions.

In today’s healthcare landscape, few things better define the role of a managed healthcare executive than managing the industry’s constant changes.